| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Lutein (L; xanthophyll carotenoid) — dietary pigment concentrated in the macula (with zeaxanthin) forming macular pigment; sourced from leafy greens (kale/spinach), corn, egg yolk, and supplements (often paired with zeaxanthin). Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Fat-soluble; absorption improves with dietary fat; plasma lutein rises dose-dependently with supplementation and accumulates in retina (macular pigment). Long-term dosing (weeks–months) is typical for tissue effects. In-vitro vs oral exposure: Most direct anti-cancer cytotoxicity requires supra-physiologic concentrations (high concentration only); clinical relevance is strongest for eye outcomes (AMD risk progression). Clinical evidence status: Supported within AREDS2-style formulations for reducing progression risk in intermediate → advanced AMD (eye-specific benefit); cancer evidence remains preclinical. Lutein-Kale, spinach, parsley, corn, egg yolks, peas -Breast cancer: Inverse correlation with dietary intake - Potent antioxidant, scavenges ROS (reactive oxygen species) -Downregulates NF-κB and other inflammatory pathways -Promotes apoptosis in cancer cells -inhibits angiogenesis Lutein — Cancer vs Normal Cell Pathway Map
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr Lutein — AD relevance: Lutein preferentially accumulates in the brain and has been linked to neural efficiency and modest cognitive performance effects in older adults; mechanisms emphasize antioxidant/anti-inflammatory protection and membrane/synaptic support. Evidence is supportive but not disease-modifying. Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Chronic intake increases circulating lutein and is associated with higher macular pigment (used as a biomarker linked to brain lutein status). Effects are generally time-dependent (months). Clinical evidence status: Small RCTs and imaging trials in older adults show signals for neural efficiency/cognition; AD-specific clinical evidence remains limited. Lutein — AD / Neurodegeneration Pathway Map
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr |
| Source: |
| Type: |
| Mood, including calmness vs aggression |
| 4232- | Lut, | Luteolin Treatment Ameliorates Brain Development and Behavioral Performance in a Mouse Model of CDKL5 Deficiency Disorder |
| - | in-vivo, | NA, | NA |
| 4231- | Lut, | Luteolin and its antidepressant properties: From mechanism of action to potential therapeutic application |
| - | Review, | AD, | NA |
| 3982- | Lut, | Zeax, | Nutritional Intervention to Prevent Alzheimer's Disease: Potential Benefits of Xanthophyll Carotenoids and Omega-3 Fatty Acids Combined |
| - | Trial, | AD, | NA |
| 3980- | Lut, | Zeax, | Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease |
| - | Trial, | AD, | NA |
| 3977- | Lut, | Zeax, | Dietary carotenoids related to risk of incident Alzheimer dementia (AD) and brain AD neuropathology: a community-based cohort of older adults |
| - | Trial, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:349 Target#:1362 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid